Phase III Study Evaluating the Efficacy and Safety of Lonsurf (trifluridine/tipiracil) in Patients with Metastatic Gastric Cancer Refractory to Standard Therapies (The TAGS Trial) Meets Primary Endpoint
Servier and Taiho Pharmaceutical Co., Ltd. announced today that the pivotal Phase III trial (TAGS) evaluating Lonsurf® (trifluridine/tipiracil) plus best supportive care (BSC) versus Placebo plus BSC in patients with advanced metastatic gastric cancer (mGC) met its primary objective to improve overall survival (OS).
These results will be submitted for presentation at an upcoming international medical conference and will be submitted to a peer-reviewed journal for publication.
About TAGS
The TAGS trial is a global, randomized, double-blind, placebo-controlled trial evaluating Lonsurf® versus Placebo in patients with pretreated metastatic gastric cancer (mGC).
The TAGS trial enrolled 507 patients who had received at least two prior regimens for mGC and who were refractory to, or unable to, tolerate further chemotherapy. Patients were randomized to receive Lonsurf® plus Best Supportive Care or placebo plus BSC in order to investigate the efficacy and safety. The primary endpoint is overall survival (OS) and secondary endpoint measures include progression free survival (PFS), safety and tolerability, as well as quality of life.
For more information on the TAGS trial, please visit https://clinicaltrials.gov/ct2/show/NCT02500043
The ClinicalTrials.gov Identifier is NCT02500043.
About Metastatic Gastric Cancer
Gastric cancer is the fifth most common cancer worldwide and the third most common cause of cancer-related death (after lung and liver cancer), with an estimate of 723,000 deaths annually1. Approximately 50% of patients with gastric cancer have advanced disease at the time of diagnosis2. Standard chemotherapy regimens for advanced gastric cancer include fluoropyrimidines, platinum derivatives, taxanes, ramucirumab or irinotecan. The addition of trastuzumab to chemotherapy is standard of care for patients with HER2-neu-positive advanced gastric cancer. However, after failure of first- and second-line therapies, standard third line treatments are limited.
About Lonsurf
Lonsurf® is an oral anticancer drug, comprising a combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity. Lonsurf® is registered in Japan, USA, European Union and in many other countries. In the European Union, Lonsurf is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan- based chemotherapies, anti-VEGF agents, and anti-EGFR agents.3
Lonsurf® is recommended by the National Institute for Health and Care Excellence (NICE).4 NCCN2 and ESMO Guidelines5 for the treatment of adult patients with metastatic colorectal cancer.
In June 2015, Servier and Taiho Pharmaceutical entered into an exclusive license agreement for the co-development and commercialization of Lonsurf®.
About Servier
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 148 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,600 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs.
Becoming a key player in oncology is part of Servier’s long-term strategy. Currently, there are nine molecular entities in clinical development in this area, targeting gastric and lung cancers and other solid tumors, as well as different types of leukemia and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics, immune, cellular and targeted therapies, to deliver life-changing medicines to patients.
More information visit: www.servier.com/en/ and www.servier-oncology.com
About Taiho Pharmaceutical Co., Ltd. (Japan)
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. (https://www.otsuka.com/en/), is an R&D-driven specialty pharma focusing on the three fields of oncology, allergy and immunology, and urology. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer, a reputation that is rapidly expanding through their extensive global R&D efforts. In areas other than oncology as well, the company creates and markets quality products that effectively treat medical conditions and can help improve people’s quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer consumer healthcare products that support people’s efforts to lead fulfilling and rewarding lives.
For more information about Taiho Pharmaceutical, please visit: https://www.taiho.co.jp/en/
More information is available at: https://servier.com/en/
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr
2. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Gastric cancer. V.1.2018.
3. European Medicines Agency. EPAR Lonsurf. Available from: http://www.ema.europa.eu/ema/
4. NICE TA405. Available at: www.nice.org.uk/guidance/TA405
5. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: Van Cutsem E et al. Ann Oncol. 2016;27:1386-422
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180508006198/en/
Contact information
Servier Media Relations
Sonia MARQUES:
media@servier.com
Tel.:
+33(0)155724021 /+33(0)784287613
or
Karine BOUSSEAU:
media@servier.com
Tel.:
+33(0)155726037
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alipay Sees Tap! Users Pass 100 Million, Accelerating Payment and AI Innovations25.4.2025 05:30:00 EEST | Press release
Alipay Tap!, a QR code-based contactless payment and customer engagement solution introduced by Alipay in China in June 2024, reports today it has won over 100 million users within 11 months. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424690776/en/ FamilyMart leverages Alipay Tap! to simplify payments and membership management. Alipay Tap! further simplifies the payment experience for both consumers and merchants compared to the “scan-and-pay” model ubiquitous in China. Users tap their unlocked phone against a merchant’s terminal or an Alipay Tap! Tag, eliminating the need to open an app, scan a code, or click through multiple screens. Data from early adopters show the solution also allows merchants to integrate customer engagement tools more seamlessly into the one-tap payment experience. FamilyMart, the nation-wide convenience store chain, reports that membership sign-ups at checkout tripled post-integration. Accord
DNIB.com Reports Internet Has 368.4 Million Domain Name Registrations at the End of the First Quarter of 202525.4.2025 00:37:00 EEST | Press release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that, according to the latest Domain Name Industry Brief Quarterly Report from DNIB.com, the first quarter of 2025 closed with 368.4 million domain name registrations across all top-level domains (TLDs), an increase of 4.2 million domain name registrations, or 1.1%, compared to the fourth quarter of 2024. Domain name registrations also increased by 6.1 million, or 1.7%, year over year. The .com and .net TLDs had a combined total of 169.8 million domain name registrations in the domain name base at the end of the first quarter of 2025, an increase of 0.8 million domain name registrations, or 0.5% compared to the fourth quarter of 2024. The .com and .net TLDs had a combined decrease of 2.6 million domain name registrations, or 1.5%, year over year. As of March 31, 2025, the .com domain name base totaled 157.2 million domain name registrations and the .ne
Smart Communications Announces Acquisition of Joisto24.4.2025 16:45:00 EEST | Press release
Smart CommunicationsTM, the leading cloud-based platform for enterprise customer communications, today announces it has acquired Joisto, a cloud data archive company. As a result, customers will now have the ability to seamlessly store, manage and retrieve digital records and documents, while meeting the stringent requirements for data retention that govern regulated industries worldwide. “We’re delighted to incorporate Joisto’s deep expertise in cloud archival into Smart Communications,” said Leigh Segall, CEO of Smart Communications. “Our leading Conversation Cloud Platform already enables our customers to manage sophisticated customer conversations at tremendous scale. With the addition of Joisto, we will extend these capabilities to meet an increasing need for regulatory-compliant and readily accessible storage of these conversations in the cloud. Together we will support customers worldwide as they continue their journey to modernize and transform customer conversations.” Joisto’s
Rimini Street Appoints Joe Locandro as EVP and Chief Information Officer to Lead Global IT Strategy24.4.2025 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the appointment of Joe Locandro as executive vice president (EVP) and chief information officer (CIO). In this role, Locandro will lead Rimini Street’s global IT operations, oversee enterprise systems strategy and drive technology innovation initiatives in support of Rimini Street’s continued growth and client success. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424168093/en/ Rimini Street Appoints Joe Locandro as EVP and Chief Information Officer to Lead Global IT Strategy Deep Technology Leadership Across Range of Industries and Regions Locandro brings more than 25 years of international leadership experience across sectors including energy, aviation, utilities, construction, and entertain
Boomi World 2025: Accelerating What’s Next in AI, Integration, and the Connected Enterprise24.4.2025 16:00:00 EEST | Press release
Boomi™, the intelligent integration and automation leader, is excited to announce that Boomi World 2025 will be held May 12-15, 2025, in Dallas, Texas. This premier event will showcase the latest advancements in AI-driven integration and automation, bringing together industry leaders, innovative thinkers, and Boomi customers and partners to explore how these technologies are reshaping the future. Attendees will gain valuable insights on how to break down silos, streamline operations, and make informed, data-driven decisions through a series of keynote sessions, breakout discussions, and hands-on training opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424969941/en/ Boomi World 2025: Accelerating What’s Next in AI, Integration, and the Connected Enterprise Emceed by technology industry veteran and correspondent Lisa Martin, Boomi World 2025 will feature esteemed speakers, including: Tara Davis-Woodhall and Hu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom